2. Antibody-drug Conjugate/ADC Related Protein Tyrosine Kinase/RTK JAK/STAT Signaling
  3. Drug-Linker Conjugates for ADC EGFR
  4. N3-PEG8-Phe-Lys-PABC-Gefitinib

N3-PEG8-Phe-Lys-PABC-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (HY-50895) (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

For research use only. We do not sell to patients.

N3-PEG8-Phe-Lys-PABC-Gefitinib

N3-PEG8-Phe-Lys-PABC-Gefitinib Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of N3-PEG8-Phe-Lys-PABC-Gefitinib:

Other Forms of N3-PEG8-Phe-Lys-PABC-Gefitinib:

N3-PEG8-Phe-Lys-PABC-Gefitinib Related Antibodies

Top Publications Citing Use of Products

View All Drug-Linker Conjugates for ADC Isoform Specific Products:

View All Isoforms
Auristatin Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents Dual payloads

View All EGFR Isoform Specific Products:

View All Isoforms
EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

  • Biological Activity

  • Purity & Documentation

  • Customer Review

Description

N3-PEG8-Phe-Lys-PABC-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (HY-50895) (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

IC50 & Target

Traditional Cytotoxic Agents

 

In Vitro

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

N3-PEG8-Phe-Lys-PABC-Gefitinib Related Antibodies
Molecular Weight

1250.80

Formula

C60H81ClFN11O15
SMILES

ClC1=C(C=CC(NC2=NC=NC3=C2C=C(C(OC)=C3)OCCCNC(OCC4=CC=C(NC([C@H](CCCCN)NC([C@@H](NC(CCOCCOCCOCCOCCOCCOCCOCCOCCN=[N+]=[N-])=O)CC5=CC=CC=C5)=O)=O)C=C4)=O)=C1)F
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (39.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.7995 mL 3.9974 mL 7.9949 mL
5 mM 0.1599 mL 0.7995 mL 1.5990 mL
View the Complete Stock Solution Preparation Table

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Complete Stock Solution Preparation Table

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 0.7995 mL 3.9974 mL 7.9949 mL 19.9872 mL
5 mM 0.1599 mL 0.7995 mL 1.5990 mL 3.9974 mL
10 mM 0.0799 mL 0.3997 mL 0.7995 mL 1.9987 mL
15 mM 0.0533 mL 0.2665 mL 0.5330 mL 1.3325 mL
20 mM 0.0400 mL 0.1999 mL 0.3997 mL 0.9994 mL
25 mM 0.0320 mL 0.1599 mL 0.3198 mL 0.7995 mL
30 mM 0.0266 mL 0.1332 mL 0.2665 mL 0.6662 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

N3-PEG8-Phe-Lys-PABC-Gefitinib Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

N3-PEG8-Phe-Lys-PABC-GefitinibDrug-Linker Conjugates for ADCEGFREpidermal growth factor receptorErbB-1HER1Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
N3-PEG8-Phe-Lys-PABC-Gefitinib
Cat. No.:
HY-131088
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.